|
1
|
Knowles MA: The genetics of transitional
cell carcinoma: Progress and potential clinical application. BJU
Int. 84:412–427. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Pudasaini S, Subedi N, Prasad KB, Rauniyar
SK, Joshi BR and Bhomi KK: Cystoscopic bladder biopsies: A
histopathological study. Nepal Med Coll J. 16:9–12. 2014.PubMed/NCBI
|
|
3
|
Ferlay J, Soerjomataram I, Dikshit R, Eser
S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: Cancer
incidence and mortality worldwide: Sources, methods and major
patterns in GLOBOCAN 2012. Int J Cancer. 136:E359–E386. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Parkin DM: The global burden of urinary
bladder cancer. Scand J Urol Nephrol Suppl. 12–20. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Boffetta P: Tobacco smoking and risk of
bladder cancer. Scand J Urol Nephrol Suppl. 45–54. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Prasad SM, Decastro GJ and Steinberg GD:
Medscape: Urothelial carcinoma of the bladder: Definition,
treatment and future efforts. Nat Rev Urol. 8:631–642. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Ministry of Health and Welfare (Taiwan), .
Taiwan Statistics of causes of death 2006. Ministry of Health and
Welfare (Taiwan); Taipei City: 2006
|
|
9
|
Moed L, Shwayder TA and Chang MW:
Cantharidin revisited: A blistering defense of an ancient medicine.
Arch Dermatol. 137:1357–1360. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Wang GS: Medical uses of mylabris in
ancient China and recent studies. J Ethnopharmacol. 26:147–162.
1989. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Karras DJ, Farrell SE, Harrigan RA,
Henretig FM and Gealt L: Poisoning from ‘Spanish fly’
(cantharidin). Am J Emerg Med. 14:478–483. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Swingle M, Ni L and Honkanen RE:
Small-molecule inhibitors of ser/thr protein phosphatases:
Specificity, use and common forms of abuse. Methods Mol Biol.
365:23–38. 2007.PubMed/NCBI
|
|
13
|
Li W, Xie L, Chen Z, Zhu Y, Sun Y, Miao Y,
Xu Z and Han X: Cantharidin, a potent and selective PP2A inhibitor,
induces an oxidative stress-independent growth inhibition of
pancreatic cancer cells through G2/M cell-cycle arrest and
apoptosis. Cancer Sci. 101:1226–1233. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Li W, Chen Z, Gong FR, Zong Y, Chen K, Li
DM, Yin H, Duan WM, Miao Y, Tao M, et al: Growth of the pancreatic
cancer cell line PANC-1 is inhibited by protein phosphatase 2A
inhibitors through overactivation of the c-Jun N-terminal kinase
pathway. Eur J Cancer. 47:2654–2664. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Li W, Chen Z, Zong Y, Gong F, Zhu Y, Zhu
Y, Lv J, Zhang J, Xie L, Sun Y, et al: PP2A inhibitors induce
apoptosis in pancreatic cancer cell line PANC-1 through persistent
phosphorylation of IKKα and sustained activation of the NF-κB
pathway. Cancer Lett. 304:117–127. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Huh JE, Kang KS, Chae C, Kim HM, Ahn KS
and Kim SH: Roles of p38 and JNK mitogen-activated protein kinase
pathways during cantharidin-induced apoptosis in U937 cells.
Biochem Pharmacol. 67:1811–1818. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Chang C, Zhu YQ, Mei JJ, Liu SQ and Luo J:
Involvement of mitochondrial pathway in NCTD-induced cytotoxicity
in human hepG2 cells. J Exp Clin Cancer Res. 29:1452010. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Huang WW, Ko SW, Tsai HY, Chung JG, Chiang
JH, Chen KT, Chen YC, Chen HY, Chen YF and Yang JS: Cantharidin
induces G2/M phase arrest and apoptosis in human colorectal cancer
colo 205 cells through inhibition of CDK1 activity and
caspase-dependent signaling pathways. Int J Oncol. 38:1067–1073.
2011.PubMed/NCBI
|
|
19
|
Zhang WD, Zhao HR, Yan Y, Wang XH, Zong ZH
and Liu Y: Apoptosis induced by cantharidin in human pulmonary
carcinoma cells A549 and its molecular mechanisms. Zhonghua Zhong
Liu Za Zhi. 27:330–334. 2005.(In Chinese). PubMed/NCBI
|
|
20
|
Huan SK, Lee HH, Liu DZ, Wu CC and Wang
CC: Cantharidin-induced cytotoxicity and cyclooxygenase 2
expression in human bladder carcinoma cell line. Toxicology.
223:136–143. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Li W, Li DM, Chen K, Chen Z, Zong Y, Yin
H, Xu ZK, Zhu Y, Gong FR and Tao M: Development of a gene therapy
strategy to target hepatocellular carcinoma based inhibition of
protein phosphatase 2A using the α-fetoprotein promoter enhancer
and pgk promoter: An in vitro and in vivo study. BMC Cancer.
12:5472012. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Xie X, Wu MY, Shou LM, Chen LP, Gong FR,
Chen K, Li DM, Duan WM, Xie YF, Mao YX, et al: Tamoxifen enhances
the anticancer effect of cantharidin and norcantharidin in
pancreatic cancer cell lines through inhibition of the protein
kinase C signaling pathway. Oncol Lett. 9:837–844. 2015.PubMed/NCBI
|
|
23
|
Hsiao YP, Tsai CH, Wu PP, Hsu SC, Liu HC,
Huang YP, Yang JH and Chung JG: Cantharidin induces G2/M phase
arrest by inhibition of Cdc25c and Cyclin A and triggers apoptosis
through reactive oxygen species and the mitochondriadependent
pathways of A375.S2 human melanoma cells. Int J Oncol.
45:2393–2402. 2014.PubMed/NCBI
|
|
24
|
Hsia TC, Yu CC, Hsu SC, Tang NY, Lu HF,
Huang YP, Wu SH, Lin JG and Chung JG: Cantharidin induces apoptosis
of H460 human lung cancer cells through mitochondria-dependent
pathways. Int J Oncol. 45:245–254. 2014.PubMed/NCBI
|
|
25
|
Kuo JH, Chu YL, Yang JS, Lin JP, Lai KC,
Kuo HM, Hsia TC and Chung JG: Cantharidin induces apoptosis in
human bladder cancer TSGH 8301 cells through mitochondria-dependent
signal pathways. Int J Oncol. 37:1243–1250. 2010.PubMed/NCBI
|
|
26
|
Evans HJ and Prosser J: Tumor-suppressor
genes: Cardinal factors in inherited predisposition to human
cancers. Environ Health Perspect. 98:25–37. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Tang C, Guo J, Chen H, Yao CJ, Zhuang DX,
Wang Y, Tang WJ, Ren G, Yao Y, Wu JS, et al: Gene mutation
profiling of primary glioblastoma through multiple tumor biopsy
guided by 1H-magnetic resonance spectroscopy. Int J Clin Exp
Pathol. 8:5327–5335. 2015.PubMed/NCBI
|
|
28
|
Heneghan HM, Miller N and Kerin MJ: MiRNAs
as biomarkers and therapeutic targets in cancer. Curr Opin
Pharmacol. 10:543–550. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Osborne C, Wilson P and Tripathy D:
Oncogenes and tumor suppressor genes in breast cancer: Potential
diagnostic and therapeutic applications. Oncologist. 9:361–377.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Ai X, Jia ZM, Wang J, Di GP, Zhang XU, Sun
F, Zang T and Liao X: Bioinformatics analysis of the target gene of
fibroblast growth factor receptor 3 in bladder cancer and
associated molecular mechanisms. Oncol Lett. 10:543–549.
2015.PubMed/NCBI
|
|
31
|
Spiegelberg C, Giedl J, Gaisa NT, Rogler
A, Riener MO, Filbeck T, Burger M, Ruemmele P, Hartmann A and
Stoehr R: Frequency of activating mutations in FGFR2 exon 7 in
bladder tumors from patients with early-onset and regular-onset
disease. Int J Clin Exp Pathol. 7:1708–1713. 2014.PubMed/NCBI
|
|
32
|
Hsia TC, Yu CC, Hsu SC, Tang NY, Lu HF, Yu
CS, Wu SH, Lin JG and Chung JG: cDNA microarray analysis of the
effect of cantharidin on DNA damage, cell cycle and
apoptosis-associated gene expression in NCI-H460 human lung cancer
cells in vitro. Mol Med Rep. 12:1030–1042. 2015.PubMed/NCBI
|
|
33
|
Lu CC, Yang JS, Chiang JH, Hour MJ, Lin
KL, Lee TH and Chung JG: Cell death caused by quinazolinone HMJ-38
challenge in oral carcinoma CAL 27 cells: Dissections of
endoplasmic reticulum stress, mitochondrial dysfunction and tumor
xenografts. Biochim Biophys Acta. 1840:2310–2320. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Chou YC, Chang MY, Wang MJ, Liu HC, Chang
SJ, Harnod T, Hung CH, Lee HT, Shen CC and Chung JG: Phenethyl
isothiocyanate alters the gene expression and the levels of protein
associated with cell cycle regulation in human glioblastoma GBM
8401 cells. Environ Toxicol. 32:176–187. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Barretina J, Caponigro G, Stransky N,
Venkatesan K, Margolin AA, Kim S, Wilson CJ, Lehár J, Kryukov GV,
Sonkin D, et al: The Cancer Cell Line Encyclopedia enables
predictive modelling of anticancer drug sensitivity. Nature.
483:603–607. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Yeh MY, Yu DS, Chen SC, Lin MS, Chang SY,
Ma CP and Han SH: Establishment and characterization of a human
urinary bladder carcinoma cell line (TSGH-8301). J Surg Oncol.
37:177–184. 1988. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Huang YP, Ni CH, Lu CC, Chiang JH, Yang
JS, Ko YC, Lin JP, Kuo JH, Chang SJ and Chung JG: Suppressions of
Migration and Invasion by Cantharidin in TSGH-8301 human bladder
carcinoma cells through the inhibitions of matrix
metalloproteinase-2/−9 signaling. Evid Based Complement Alternat
Med. 2013:1902812013.PubMed/NCBI
|
|
38
|
Su CC, Liu SH, Lee KI, Huang KT, Lu TH,
Fang KM, Wu CC, Yen CC, Lai CH, Su YC and Huang CF: Cantharidin
induces apoptosis through the calcium/PKC-regulated endoplasmic
reticulum stress pathway in human bladder cancer cells. Am J Chin
Med. 43:581–600. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Hensel J, Duex JE, Owens C, Dancik GM,
Edwards MG, Frierson HF and Theodorescu D: Patient mutation
directed shRNA screen uncovers novel bladder tumor growth
suppressors. Mol Cancer Res. 13:1306–1315. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Ayala F, Dewar R, Kieran M and Kalluri R:
Contribution of bone microenvironment to leukemogenesis and
leukemia progression. Leukemia. 23:2233–2241. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Straussman R, Morikawa T, Shee K,
Barzily-Rokni M, Qian ZR, Du J, Davis A, Mongare MM, Gould J,
Frederick DT, et al: Tumour micro-environment elicits innate
resistance to RAF inhibitors through HGF secretion. Nature.
487:500–504. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Wilson TR, Fridlyand J, Yan Y, Penuel E,
Burton L, Chan E, Peng J, Lin E, Wang Y, Sosman J, et al:
Widespread potential for growth-factor-driven resistance to
anticancer kinase inhibitors. Nature. 487:505–509. 2012. View Article : Google Scholar : PubMed/NCBI
|
